Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 740

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 740
---
815. Earnings per Share Basic net loss per common share is computed by dividing the net loss applicable to common shareholders by the weighted -averagenumber of common shares outstanding during the year. Diluted loss per common share is computed similar to basic loss per share, except that the denominator is increased to include the number of additional potential common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Potential common shares are excluded from the diluted loss per common share computation for a period in which a net loss is reported or if their effect is anti -dilutive. Since the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti -dilutive.

A summary of the potentially dilutive securities that were excluded from diluted net loss per share each year because their effect would be antidilutive are presented as follows:

|                                 |     | December 31, |     |         |     |         |
|                                 |     |         2024 |     |    2023 |     |    2022 |
| Stock Options                   |     |       34,417 |     |  46,591 |     |  33,328 |
| Warrants (excluding pre-funded) |     |    1,455,288 |     | 332,450 |     | 332,450 |
| Convertible preferred shares    |     |      206,452 |     |       — |     |       — |
|                                 |     |    1,696,157 |     | 379,041 |     | 365,778 |

Adjusted for the effect of a 1 -to-40reverse share split that was effective September 27, 2024 Segment Reporting The Company manages its operations as a single segment for the purpose of assessing performance and making operating decisions. The Company’s singular focus is on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. All of the Company’s tangible assets are held in Switzerland. Operating segments are defined as components of an entity for which separate financial information is available and that is regularly provided to the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s Chief Executive Officer is the Company’s CODM. The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating